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Abstract
Background: Use of  tobacco is often implicated in the development of  oral diseases. Questionable accuracy of  the traditional 
questionnaires to assess cigarette exposure necessitates the use of  biomarkers like thiocyanate which provide a definitive quan-
titative measure.
Objective: To assess the rise in the level of  thiocyanate for measurement of  smoking behaviour in adults.
Materials and methods: Serum and salivary thiocyanate levels were estimated in 20 non-smokers, 20 ex-smokers and 40 smok-
ers. Smokers were divided into two groups based on the presence or absence of  oral mucosal lesions.
Results: The mean serum and salivary thiocyanate levels were increased significantly in smokers when compared to non-smok-
ers and ex-smokers. The levels were not significantly different between ex-smokers and non-smokers and between smokers 
with tobacco related oral mucosal lesions and those without. Statistically significant correlation was seen between the serum and 
salivary levels of  thiocyanate.
Conclusion: This study highlights the high level of  thiocyanate in the serum and saliva of  smokers when compared to non-smok-
ers and ex-smokers. Significant increase in thiocyanate level was also seen in saliva. Hence it can be stated that saliva can be used 
as a reliable, non-invasive tool to assess smoking behaviour in the population and its changes over time.
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Tobacco use is one of  the greatest challenges that is 
faced by the global healthcare today. Approximately 33% 
of  the adult population consumes tobacco in one form 
or the other.1 Risk factors such as use of  tobacco prod-
ucts, alcohol consumption, betel nut chewing and human 
papilloma virus have been linked to the development of  
lesions like smoker’s palate, leukoplakia, erythroplakia, 
oral submucous fibrosis and erosive lichen planus. These 
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potentially malignant disorders along with oral carcino-
mas cause significant morbidity and mortality in patients. 
Oral cancer is one of  the leading causes of  death in India 
with incidence rates standing at 53842 cases in males and 
23161 cases in females.2,3 As there exists a long time lapse 
between the use of  tobacco and the appearance of  dis-
ease, the effect of  today’s globalization of  tobacco mar-
ket will be felt for decades to come.1
Tobacco diminishes quality of  life, beginning with things 
as modest as halitosis to as intricate as developmental 
abnormalities in children whose mothers were smok-
ers during pregnancy. Tobacco is known to decrease the 
body’s immune response and is a well-known cause for 
the development of  adult periodontitis, oral cancer and 
oral cancer recurrence.1 The use of  tobacco has been 
positively linked to the development of  leukoplakia and 
oral submucous fibrosis which have a potential for malig-
nant transformation.3 It is seen that there exists a clear 
dose-response relationship between smoking and oral 
cancer. Some studies show that, after a decade of  quit-
ting, the risk of  development of  cancer was the same as 
that of  non-smokers while other studies found that the 
risk in ex-smokers was marginally increased.4,5
Traditionally, measurement of  exposure to cigarettes has 
been done through questionnaires. The exactness of  such 
a method is limited due to cognizant false reporting as 
well as insufficient recognition of  the true degree of  ex-
posure.6 To overcome this hurdle, various biochemical 
markers of  cigarette smoke like carbon monoxide, nic-
otine, cotinine and thiocyanate have been used as mea-
sures of  smoking behaviour in the recent years.6 The long 
biologic half-life of  thiocyanate (10-14 days) makes it an 
ideal substrate to determine habitual smoking behaviour.7
The combustion of  nitrogen containing compounds 
found in cigarettes leads to inhalation of  hydrogen cy-
anide (HCN) gas which is ultimately assimilated into the 
body as cyanide (CN-). This inhibits the activity of  cyto-
chrome oxidase.8 Cyanide is gradually released from its 
bond with ferric ion and is metabolized to thiocyanate 
after accepting a sulfur atom from a sulfur donor such as 
thiosulfate. This reaction is catalyzed by thiosulfate trans-
ferase.9 The thiocyanate level in plasma is considered to 
be a good indicator of  exposure to cyano-containing or-
ganic substances since thiocyanate levels are inexorably 
high when the plasma cyanide levels are high.9 Saliva also 
shows high levels of  thiocyanate and the physiologic role 
of  thiocyanate in saliva maybe due to hypothiocyanate 
(HOSCN) which produces an antibacterial effect by the 
action of  salivary peroxides.8
With the current study we aimed to measure the level 
of  thiocyanate in the serum and saliva of  non-smokers, 
ex-smokers and smokers to determine its efficacy as a 
biochemical marker of  smoking behaviour.
Materials and methods
The present study was  an observational study conducted 
on subjects reporting to the Department of  Oral Medi-
cine and Radiology at a Dental Science Institute in South 
India. The sample population consisted of  semi-urban 
and rural subjects.
Sample size was determined based on the pilot study per-
formed. A sample of  17.5 was determined as the mini-
mum in each group to estimate and to calculate for the 
statistical analysis. We rounded 17.5 into 20 so as to re-
duce errors.  Therefore, the study sample included a to-
tal of  80 subjects who were divided into the following 
groups:
Control Group (C): 20 subjects who were non-smokers 
of  tobacco products.
Group I (G1): 20 subjects who were ex-smokers of  to-
bacco products.
Group II (G2): 40 subjects who were smokers of  tobac-
co products.
Sub-Group IIa (G2a): 20 subjects who were smokers of  
tobacco products without oral mucosal lesions associated 
with any tobacco related disorders.
Sub-Group IIb (G2b): 20 subjects who were smokers 
of  tobacco products with oral mucosal lesions associated 
with tobacco related disorders.
Strict inclusion criteria were followed for the control 
group and the study groups. Healthy non-smoker sub-
jects in the age group of  18-60 years, without any histo-
ry of  oral and systemic diseases were taken as controls. 
Group I consisted of  subjects who were in the age group 
of  18-60 years who used to smoke one or more than one 
pack of  hand rolled or manufactured tobacco products 
per day but had quit since the last 1 year. Group II con-
sisted of  subjects who were in the same age group who 
regularly smoked one or more than one pack of  hand 
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rolled or manufactured tobacco products per day since 
the last 1 year or more. This group was subdivided into 
GIIa consisting of  subjects who did not present with oral 
mucosal lesions associated with any tobacco related dis-
orders. GIIb consisted of  subjects who presented with 
oral mucosal lesions associated with tobacco related dis-
orders including, but not restricted to, leukoplakia, eryth-
roplakia, stomatitis nicotina, smoker’s melanosis and oral 
squamous cell carcinoma.
Subjects with a history of  any long term systemic diseas-
es or acute infections, subjects who were on any med-
ications like erythromycin, nitroprusside, chlorambucil, 
ifosfamide and melphalan, and subjects with a positive 
history of  tobacco chewing habits were excluded from 
the study. Each patient was thoroughly examined both 
intra orally and extra orally under artificial illumination.
 
Method of  collection of  data
Sample collection:
Informed consent was obtained from the patients in-
cluded in the study. Ethical clearance was obtained from 
the Institutional Ethical Committee. Detailed case his-
tory was recorded along with thorough examination of  
the oral cavity. Collection of  serum and saliva was done 
between 9 a.m and 12 p.m to minimize possible diurnal 
variations in sampling.
Saliva collection:
All salivary samples were collected from patients 2 hours 
after food using spit technique. The patient was asked to 
sit in the dental chair with the head tilted forward and 
instructed not to speak or swallow any saliva. Then the 
patient was instructed to spit into a sterile graduated con-
tainer every minute for 5-8 minutes. Salivary sample rep-
resented whole mouth fluid. The collected sample was 
centrifuged at 3000 rpm for 10 minutes and the superna-
tant was collected and stored at -200C.
Blood collection:
5 ml of  venous blood was collected from the antecubital 
vein with syringe and placed in vials. Serum was then ex-
tracted and stored at temperature of  -4˚C in glass vials.
Reagents used:
• Bromine water, saturated
• Arsenious oxide
• 20 g of  As2O3 per litre of  0.1 molar NaOH, titrated to 
neutral (phenolphthalein endpoint)
• p-phenylenediamine
• 2 g/liter of  0.5 molar HCl
• Pyridine reagent
• Pyridine-concentrated HCl-de-ionized water, 6:1:4 by 
volume
•  Pyridine-p-phenylenediamine reagent
• Pyridine reagent-p-phenylenediamine reagent, 3:1 by 
volume
Procedure
Estimation of  thiocyanate in serum or saliva:
Serum (1 ml) was separated and de-proteinized by adding 
trichloroacetic acid (9 ml of  a 10 g/100 ml solution).
Portions (1 ml) of  the supernatant fluid were then ana-
lyzed for thiocyanate.
A portion (1 ml) of  the test solution (serum or saliva) was 
acidified (0.5 ml of  1 mol/litre HCl) and bromine water 
was added (2 drops of  saturated solution), followed, af-
ter mixing, by the addition of  arsenious oxide solution (3 
drops) to remove excess bromine.
Any traces of  free bromine remaining were removed un-
der reduced pressure.
The pyridine-p-phenylenediamine reagent (1.8 ml) was 
then added and the absorbance of  the resultant red-
dish-pink dyestuff  was read against a reagent blank, 
the readings being taken within 10 mm at a wavelength 
known to be isosbestic point for this reaction.
This wavelength was determined by examination of  the 
color reaction in a recording spectrophotometer and was 
generally found at 520 nm. The absorbance so obtained 
was plotted against a graph to get the thiocyanate concen-
tration. The optical density of  the pink color formed was 
directly proportional to the thiocyanate concentration in 
the sample.
Calculation
Direct proportionality was observed between the optical 
density of  the test samples and thiocyanate concentra-
tion. Calculation was done by plotting against the stan-
dard graph with the X-axis showing thiocyanate and 
Y-axis showing the optical density. It was multiplied by 
the respective dilution factors and the final concentration 
was expressed as µM/l.
Statistical analysis
The data obtained from study was analyzed using SPSS 
version 17.0 software. One way ANOVA test was used 
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for analysis of  thiocyanate levels in all groups. Post-
hoc Tukey’s test was used for the comparison of  Study 
Groups to the Control Group and the Study Groups 
with each other. Student’s T test was used for compari-
son between smokers with and without oral mucosal le-
sions associated with tobacco related disorders. Pearson’s 
Co-relation Co-efficient was used to correlate the chang-
es in the levels of  serum and salivary thiocyanate levels 
between the Study Groups and the Control Group and 
the Study Groups with each other. P< 0.05 was consid-
ered significant.
Results
Demographic data analysis of  the groups
The age range of  subjects was 19-60 years in Group C as 
well as in Group II while it was 19-58 years in Group I. 
All the groups consisted of  only male subjects. The mean 
age in Group C was 41.9 ± 14.51 years while in Group I 
and Group II were 44.35 ± 13.84 years and 43.7 ± 12.87 
years respectively.
Among the 20 smokers who showed the presence of  oral 
mucosal lesions associated with tobacco related disorders, 
9 subjects had smoker’s melanosis, 5 had oral homoge-
neous leukoplakia, 3 had oral cancer and 3 had smoker’s 
palate.
Analysis of  mean serum and salivary thiocyanate 
levels in non-smokers, ex-smokers and smokers
Mean serum thiocyanate levels
The mean serum thiocyanate levels in Group C was 58.67 
± 2.48 µM/l while the mean serum thiocyanate levels 
of  Group I and Group II were 58.47 ± 2.67 µM/l and 
142.71 ± 3.05 µM/l respectively. (Table 1, Figure 1)
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GROUPS N Mean Std. Deviation Statistics/ mean squares df2(welch) / F(Anova) P VALUE
SERUM NON-SMOKERS 20 58.6725 2.477702 70788.03 8872.87 <0.001
EX-SMOKERS 20 58.4695 2.668215
SMOKERS 40 142.7065 3.048325
Total 80 100.6388 42.42497
SALIVA NON-SMOKERS 20 1551.305 138.7472 22501364 1204.709 <0.001
EX-SMOKERS 20 1554.282 142.0102
SMOKERS 40 3052.838 132.9409
Total 80 2302.816 766.7201
TABLE 1: Comparison of serum and salivary levels of thiocyanate using one way ANOVA
730
 
Figure 1: Graphs showing mean serum and salivary thiocyanate levels in non-smokers, ex-smokers and 
smokers. 
Mean salivary thiocyanate levels:
The mean salivary thiocyanate levels in Group C was 
1551.305 ± 138.75 µM/l, while the mean salivary thiocy-
anate levels of  Group I and Group II were 1554.282 ± 
142.01 µM/l and 3052.838 ± 132.94 µM/l respectively. 
(Table 1, Figure 1)
Analysis of  statistical significance
Serum thiocyanate levels:
When serum levels of  thiocyanate were compared be-
tween Group C (58.67 ± 2.48 µM/l) and Group I (58.47 
± 2.67 µM/l), the difference was not statistically signif-
icant (p = 0.972). When the serum levels of  thiocya-
nate in Group C was compared with Group II (142.71 
± 3.05 µM/l), highly significant difference was obtained 
(p<0.001). Statistical comparison of  serum levels of  thio-
cyanate between Group I and Group II again showed 
highly significant difference (p<0.001). (Table 2)
Salivary thiocyanate levels:
When salivary levels of  thiocyanate were compared be-
tween Group C (1551.305 ± 138.75 µM/l) and Group 
I (1554.282 ± 142.01 µM/l), the difference was not sta-
tistically significant (p = 0.997). When the salivary levels 
of  thiocyanate in Group C was compared with Group II 
(3052.838 ± 132.94 µM/l), highly significant difference 
was obtained (p<0.001). Statistical comparison of  sali-
vary levels of  thiocyanate between Group I and Group II 
showed highly significant difference (p<0.001). (Table 2)
Serum and salivary thiocyanate between Group IIa and 
Group IIb (142.733 ± 2.99 µM/l; 142.68 ± 3.18 µM/l 
and 3056.899 ± 128.42 µM/l; 3048.777 ± 140.53 µM/l) 
were compared using Student’s T-Test. The differences 
were not statistically significant (p = 0.957 and p = 0.85). 
(Table 3)
Table 2: Comparison of serum and salivary levels of thiocyanate 



























 0.203 0.893198 0.972 
Smokers -84.0340000* 0.773532 <0.001 
Ex-
smokers 





-2.977 43.21787 0.997 
Smokers -1501.5325000* 37.42778 <0.001 
Ex-
smokers 
Smokers -1498.5555000* 37.42778 <0.001 
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Correlation of  serum thiocyanate with salivary thio-
cyanate levels among the groups
Pearson’s Correlation coefficient was used to correlate 
the serum and salivary thiocyanate between the groups. 
Excellent correlation was observed between the level 
of  thiocyanate in the serum and saliva in Group C (r = 
0.954) (Table 4, Figure 2), Group I (r = 0.947) (Table 4, 
Figure 2), Group II (r = 0.967) (Table 4, Figure 2), Group 
IIa(r = 0.977) (Table 5, Figure 3) and Group IIb (r = 0. 
.959) (Table 5, Figure 3).
 
Figure 2: Correlation of serum and salivary thiocyanate levels using Pearsons correlation (Group C. 
Group I, Group II). 
Table 3: Comparison of serum and salivary levels of thiocyanate among smokers with  




  Group N Mean 
Std. 
Deviation t df p VALUE 
Serum 
Smokers with oral mucosal 
lesions associated with 
tobacco related disorders 20 142.68 3.183973 
-0.054 38 0.957 
Smokers without oral 
mucosal lesions associated 
with tobacco related disorders 20 142.733 2.989059 
Saliva 
Smokers with oral mucosal 
lesions associated with 
tobacco related disorders 20 3048.777 140.5342 
-0.191 38 0.85 
Smokers without oral 
mucosal lesions associated 
with tobacco related disorders 20 3056.899 128.4217 
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Figure 3: Correlation of serum and salivary thiocyanate levels using Pearsons correlation (Group IIa, 
Group IIb). 
Table 4: Correlation of serum and salivary levels of thiocyanate among 






Table 5: Correlation of serum and salivary levels of thiocyanate among 
smokers with and without oral mucosal lesions associated with tobacco 








Correlations   
Group Serum 
Non-smokers Saliva Pearson 
Correlation 
.954 
Sig. (2-tailed) <0.001 
N 20 
Ex-smokers Saliva Pearson 
Correlation 
.947 
Sig. (2-tailed) <0.001 
N 20 
Smokers Saliva Pearson 
Correlation 
.967 
Sig. (2-tailed) <0.001 
N 40 
Correlations   
Group Serum 
Smokers without 
oral  mucosal lesions 





Sig. (2-tailed) <0.001 
N 20 
Smokers with 
oral  mucosal lesions 





Sig. (2-tailed) <0.001 
N 20 
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Discussion
The harmful effects of  smoking on oral health are well 
established. Smoking affects both the adoptive and innate 
arms of  the immune system. It augments pro-inflamma-
tory cytokine production and reduces the anti-inflamma-
tory cytokine levels thereby leading to the disease pro-
cess.10 It has been linked to the etiology of  oral cancer, 
pre-cancer, periodontitis, caries, tooth loss and other soft 
tissue changes.11
Although the levels of  thiocyanate are known to increase 
tremendously on exposure to tobacco smoke, several 
other factors like industrial cyanide exposure and drugs 
like sodium nitroprusside cause serum thiocyanate levels 
to rise. Serum thiocyanate levels are also elevated on in-
gestion of  certain food such as turnips, horseradish, the 
cabbage family, garlic, mustard, beer and almond. Here, 
3-indolylglucothiocyantes are split by thioglucosidase 
into glucose and isothiocyanates. Isothiocyanates are then 
converted into thiocyanate by thiocyanate isomerase.6 Zil-
a-Rubab et al found that although thiocyanate levels do 
vary according to diet and atmospheric exposure, the lev-
els in smokers far exceeded that of  passive smokers and 
non-smokers.12 It has also been reported that alimentary 
sources such as cyanogenic food do not affect thiocya-
nate levels in the saliva.8 Therefore a significant increase 
in thiocyanate levels can be considered to be specific to 
smoking habit while the thiocyanate in blood is mainly 
distributed in the serum and its presence indicates detox-
ification of  cyanide from a more varied source.12 Thus 
salivary thiocyanate level could be used as a determinant 
of  regularsmoking patterns.
In the current study, the mean serum as well as salivary 
thiocyanate levels of  smokers were more than twice that 
of  non-smokers. This was in accordance with the study 
by Vogt et al who stated that the rise in serum thiocya-
nate level in smokers was due to the minute amounts of  
cyanide present in the tobacco smoke.6 Thus it can be in-
ferred that the two-week biologic half-life of  thiocyanate 
makes it an ideal substrate to measure habitual smoking 
behaviour.
It was observed in the present study that there was no 
correlation between the age of  study subjects and their 
serum and salivary thiocyanate levels which is in accor-
dance with the study by Tsuge et al8 who found that al-
though smokers showed higher levels of  thiocyanate in 
their serum and saliva in comparison with non-smokers, 
there was no correlation between the age of  the subjects 
and the thiocyanate levels. It was seen that all subjects in 
the study were males which can be attributed to the social 
constraints of  the rural and semi urban study population 
included in the study.
In the present study, the mean serum thiocyanate level in 
ex-smokers was 58.47 ± 2.67 µM/l which was markedly 
decreased when compared to the level in smokers. This 
is a unique feature of  this study as, to the best of  our 
knowledge, we did not find any report in existing litera-
ture where the serum thiocyanate level was measured in 
ex-smokers. Thus quantification of  thiocyanate level in 
the serum can be used as a measure of  extent of  compli-
ance in tobacco cessation practices.
There exists a statistically significant difference between 
the levels of  salivary thiocyanate in non-smokers and 
smokers as well as between ex-smokers and smokers. But 
the difference was not statistically significant between 
non-smokers and ex-smokers. This is in accordance with 
the study conducted by Luepker et al13 who found that 
salivary thiocyanate levels increased in smokers but not in 
non-smokers, light smokers and self-declared ‘quit’ smok-
ers. Thus the elevated salivary thiocyanate level could be 
associated with regular cigarette use which thereby deter-
mined the smoking patterns.
In the present study, the mean serum and salivary thiocy-
anate level in ex-smokers was markedly decreased when 
compared to smokers. Thus quantification of  thiocyanate 
level can be used as a measure of  compliance to tobacco 
cessation practices. The present study showed excellent 
positive correlation between the serum and salivary levels 
of  thiocyanate in all the study groups and also showed 
that the salivary values were higher than the serum values. 
Degiampietro et al14 also found that the concentration 
of  thiocyanate in parotid saliva as well as whole saliva 
was approximately thirty times higher than the level in 
plasma. Thus it could be hypothesized that thiocyanate 
must accumulate in the parotid gland and is then secreted 
through a process which is yet undetermined.
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Smoking weakens humoral as well as cell mediated im-
mune responses. There is a severe compromise in the 
oxygen uptake by polymorphonuclear cells (PMN) and 
production of  oxygen radicals. This collectively leads to 
impairments in both the phagocytic as well as the chemo-
tactic capability of  leucocytes of  smokers.15 This mecha-
nism could contribute to various oral diseases in smokers.
In the present study, among the 20 smokers who demon-
strated oral mucosal lesions, the highest prevalence was 
for smoker’s melanosis followed by oral homogeneous 
leukoplakia. Oral cancer and smoker’s palate were found 
next in the order. The presence of  soft tissue lesions in 
tobacco users can be ascribed to the irritation caused by 
tobacco to the oral structures. Genetic and host factors 
such as dysregulation of  adhesion molecule, reduced T 
cell antigen response, alteration in the neutrophil activi-
ty and platelet aggregation could also affect the immune 
system.16 However, the present study showed no statisti-
cally significant difference between the thiocyanate levels 
in the serum and saliva of  smokers with and without to-
bacco associated oral mucosal lesions. This may be due 
to the cross-sectional design which was employed in the 
present study which may not indicate the true temporal 
relationship between thiocyanate levels and the develop-
ment of  oral mucosal lesions.
The biologic half-life of  thiocyanate is 7-14 days.7,8 
Therefore, in ex-smokers who have abstained from the 
habit, the level of  thiocyanate gradually decreases to the 
level seen in non-smokers. Hence the inclusion of  the 
ex-smoker group can be considered as another limitation 
of  this study. However, we wanted to check for the pos-
sible role of  thiocyanate in the development of  oral mu-
cosal lesions that are commonly found among smokers 
since thiocyanate decreases immune response and acts as 
a stimulant to pro-inflammatory mediators. 
As significant increase of  thiocyanate level is observed 
both in serum and saliva, this study suggests the use of  
thiocyanate as a potential biomarker for determining 
smoking behaviour in adults. In addition, an excellent 
positive correlation was observed between the thiocya-
nate levels in the serum and saliva thereby indicating that 
saliva could be a reliable and non-invasive tool indiagno-
sis, monitoring and management of  oral mucosal lesions 
associated with tobacco related disorders.
Conclusion
The increase in serum and salivary levels of  thiocyanate 
in smokers shows promise towards the use of  thiocya-
nate to validate smoking behaviour. The determination 
of  thiocyanate levels in ex-smokers can help establish 
thiocyanate as a potential biomarker in tobacco cessation 
studies, to investigate the authenticity of  self-reported 
smoking behaviour and to confirm the absorption of  
specific smoke constituents in a quantitative manner. 
These informative biomarkers can further serve as early 
sentinels of  disease and have been considered as the most 
promising alternative to existing epidemiological data.
Saliva can be considered as the mirror of  the body’s 
health. Thus the findings of  the present study indicate 
that estimation of  thiocyanate could determine the smok-
ing behaviour by using saliva, which is augmented by the 
ease of  its collection and its non-invasive nature.
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